CLU

2,6-DICHLORO-N-IMIDAZOLIDIN-2-YLIDENEANILINE

Created:	2007-05-01
Last modified:	2021-03-01

Find Related PDB Entry
2 entries where CLU is found as a standalone ligand

Find related ligands: Help
Similar Ligands (Stereospecific) Similar Ligands (including Stereoisomers) Similar Ligands (Quick Screen) Similar Ligands (Substructure Stereospecific) Similar Ligands (Substructure including Stereoisomers)

Chemical Details
Formal Charge	0
Atom Count	23
Chiral Atom Count	0
Bond Count	24
Aromatic Bond Count	6

Toggle Hydrogen Toggle Labels

Chemical Component Summary
Name	2,6-DICHLORO-N-IMIDAZOLIDIN-2-YLIDENEANILINE
Synonyms	CLONIDINE
Systematic Name (OpenEye OEToolkits)	N-(2,6-dichlorophenyl)imidazolidin-2-imine
Formula	C₉ H₉ Cl₂ N₃
Molecular Weight	230.094
Type	NON-POLYMER

Chemical Descriptors
Type	Program	Version	Descriptor
SMILES	ACDLabs	10.04	Clc2c(\N=C1/NCCN1)c(Cl)ccc2
SMILES	CACTVS	3.341	Clc1cccc(Cl)c1N=C2NCCN2
SMILES	OpenEye OEToolkits	1.5.0	c1cc(c(c(c1)Cl)N=C2NCCN2)Cl
Canonical SMILES	CACTVS	3.341	Clc1cccc(Cl)c1N=C2NCCN2
Canonical SMILES	OpenEye OEToolkits	1.5.0	c1cc(c(c(c1)Cl)N=C2NCCN2)Cl
InChI	InChI	1.03	InChI=1S/C9H9Cl2N3/c10-6-2-1-3-7(11)8(6)14-9-12-4-5-13-9/h1-3H,4-5H2,(H2,12,13,14)
InChIKey	InChI	1.03	GJSURZIOUXUGAL-UHFFFAOYSA-N

Drug Info: DrugBank

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License

DrugBank ID	DB00575
Name	Clonidine
Groups	investigational approved
Description	Clonidine is an imidazole derivate that acts as an agonist of alpha-2 adrenoceptors.[A180559] This activity is useful for the treatment of hypertension, severe pain, and ADHD.[L7237,L54536,L7240,L7243,L7246] Clonidine was granted FDA approval on 3 September 1974.[L7237]
Synonyms	2-((2,6-Dichlorophenyl)imino)imidazolidine Clonidin Clonidine hydrochloride Clonidine Chlofazoline Clonidina 2,6-Dichloro-N-2-imidazolidinylidenebenzenamine Clonidinum
Brand Names	Clonidine Hydrochloride Extended-Release Clonidine Transdermal System USP, 0.2 mg/day Teva-clonidine Mar-clonidine Onyda XR Apo-clonidine Tab 0.1mg Clonidine HCl Tab 0.2mg Clonidine 0.1 Ntp-clonidine Catapres-TTS Clonidine hydrochloride extended-release Sandoz Clonidine Combipres 0.1/15 Tab Catapres Tab 0.2mg Clonidine Clonidine transdermal system Mint-clonidine Catapres-TTS-3 Nu-clonidine Tab 0.2mg Nexiclon XR Clonidine Transdermal System USP, 0.3 mg/day Clonidine Hydrochloride Clonidine HYDROCHLORIDE Apo-clonidine Tab 0.2mg Apo-clonidine Dom-clonidine Clonidine Transdermal System USP, 0.1 mg/day Javadin Clorpres Catapres Tab 0.1mg Catapres Catapres-TTS-2 Kapvay Duraclon Nexiclon Nu-clonidine Tab 0.1mg Clonidine hydrochloride Dixarit Tab 0.025mg Jamp Clonidine Clonidine Hci Catapres-TTS-1
Indication	Clonidine tablets, oral solution and transdermal systems are indicated for the treatment of hypertension alone or in combination with other medications.[L7237,L7240, L54536] A clonidine injection is indicated for use with opiates in the treatment of severe cancer pain where opiates alone are insufficient.[L7243] An extended-release tablet of clonidine is indicated for the treatment of ADHD, either alone or in combination with other medications.[L7246] Clonidine is also used for the diagnosis of pheochromocytoma,[A180565] treatment of nicotine dependance,[A180568] and opiate withdrawal.[A180571] Additionally, clonidine is also indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as a monotherapy or as an adjunctive therapy to central nervous system (CNS) stimulant medications in pediatric patients 6 years of age and older.[L52295,L52300]
Categories	Adrenergic Agents Adrenergic Agonists Adrenergic alpha-1 Receptor Agonists Adrenergic alpha-2 Receptor Agonists Adrenergic alpha-Agonists Agents producing tachycardia Agents that produce hypertension Analgesics Anesthetics Anesthetics, General Antiadrenergic Agents, Centrally Acting Antiglaucoma Preparations and Miotics Antihypertensive Agents Antihypertensive Agents Indicated for Hypertension Antimigraine Preparations Autonomic Agents Bradycardia-Causing Agents Cardiovascular Agents Central alpha-2 Adrenergic Agonist Central Alpha-agonists Central Nervous System Agents Central Nervous System Depressants Cytochrome P-450 CYP1A1 Substrates Cytochrome P-450 CYP1A2 Substrates Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index Cytochrome P-450 CYP2D6 Substrates Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index Cytochrome P-450 CYP3A Substrates Cytochrome P-450 CYP3A4 Substrates Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index Cytochrome P-450 CYP3A5 Substrates Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index Cytochrome P-450 Substrates Hypotensive Agents Imidazoles Imidazoline Receptor Agonists Imidazolines Narrow Therapeutic Index Drugs Nervous System Neurotransmitter Agents Ophthalmologicals Peripheral Nervous System Agents Sensory Organs Sensory System Agents Sympatholytics Sympathomimetics in Glaucoma Therapy
ATC-Code	S01EA04 C02LC01 C02AC01 N02CX02 C02LC51
CAS number	4205-90-7

Drug Targets

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License

Name	Target Sequence	Pharmacological Action	Actions
Alpha-2B adrenergic receptor	MDHQDPYSVQATAAIAAAITFLILFTIFGNALVILAVLTSRSLRAPQNLF...	unknown	agonist
Alpha-2C adrenergic receptor	MASPALAAALAVAAAAGPNASGAGERGSGGVANASGASWGPPRGQYSAGA...	unknown	agonist
Alpha-2A adrenergic receptor	MFRQEQPLAEGSFAPMGSLQPDAGNASWNGTEAPGGGARATPYSLQVTLT...	unknown	agonist
Amine oxidase [copper-containing] 3	MNQKTILVLLILAVITIFALVCVLLVGRGGDGGEPSQLPHCPSVSPSAQP...	unknown	inhibitor
Alpha-1A adrenergic receptor	MVFLSGNASDSSNCTQPPAPVNISKAILLGVILGGLILFGVLGNILVILS...	unknown	agonist
Alpha-1B adrenergic receptor	MNPDLDTGHNTSAPAHWGELKNANFTGPNQTSSNSTLPQLDITRAISVGL...	unknown	agonist
Alpha-1D adrenergic receptor	MTFRDLLSVSFEGPRPDSSAGGSSAGGGGGSAGGAAPSEGPAVGGVPGGA...	unknown	agonist
Cytochrome P450 1A2	MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPL...	unknown	substrate
Cytochrome P450 3A4	MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI...	unknown	substrate
Cytochrome P450 1A1	MLFPISMSATEFLLASVIFCLVFWVIRASRPQVPKGLKNPPGPWGWPLIG...	unknown	substrate
Cytochrome P450 3A5	MDLIPNLAVETWLLLAVSLVLLYLYGTRTHGLFKRLGIPGPTPLPLLGNV...	unknown	substrate
Cytochrome P450 2D6	MGLEALVPLAVIVAIFLLLVDLMHRRQRWAARYPPGPLPLPGLGNLLHVD...	unknown	substrate
Albumin	MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIA...	unknown	binder
Solute carrier family 22 member 3	MPSFDEALQRVGEFGRFQRRVFLLLCLTGVTFAFLFVGVVFLGTQPDHYW...	unknown	inhibitor
Organic cation/carnitine transporter 2	MRDYDEVTAFLGEWGPFQRLIFFLLSASIIPNGFTGLSSVFLIATPEHRC...	unknown	inhibitor
Solute carrier family 22 member 4	MRDYDEVIAFLGEWGPFQRLIFFLLSASIIPNGFNGMSVVFLAGTPEHRC...	unknown	inhibitor
View More

Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682